The well-established role of NF-κB in AD pathogenesis solidifies its standing as a rational and scientifically grounded therapeutic target, bolstering the credibility of NF-κB inhibition as a plausible avenue for effective AD treatment. Here, NFKB1 is linked to Alzheimer disease.